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OBJECTIVE—Hepatic triglyceride is closely associated with
hepatic insulin resistance and is known to be decreased by thiazo-
lididinediones. We studied the effect of pioglitazone on hepatic
triglyceride content and the consequent effect on postprandial
endogenous glucose production (EGP) in type 2 diabetes.
RESEARCH DESIGN AND METHODS—Ten subjects with
type 2 diabetes on sulfonylurea therapy were treated with
pioglitazone (30 mg daily) for 16 weeks. EGP was measured
using a dynamic isotopic methodology after a standard liquid test
meal both before and after pioglitazone treatment. Liver and
muscle triglyceride levels were measured by
1H magnetic reso-
nance spectroscopy, and intra-abdominal fat content was mea-
sured by magnetic resonance imaging.
RESULTS—Pioglitazone treatment reduced mean plasma fast-
ing glucose and mean peak postprandial glucose levels. Fasting
EGP decreased after pioglitazone treatment (16.6  1.0 vs. 12.2 
0.7 mol  kg
1  min
1, P  0.005). Between 80 and 260 min
postprandially, EGP was twofold lower on pioglitazone (2.58 
0.25 vs. 1.26  0.30 mol  kg
1  min
1, P  0.001). Hepatic
triglyceride content decreased by 50% (P  0.03), and muscle
(anterior tibialis) triglyceride content decreased by 55% (P 
0.02). Hepatic triglyceride content was directly correlated with
fasting EGP (r  0.64, P  0.01) and inversely correlated to
percentage suppression of EGP (time 150 min, r  0.63, P 
0.02). Muscle triglyceride, subcutaneous fat, and visceral fat
content were not related to EGP.
CONCLUSIONS—Reduction in hepatic triglyceride by pioglita-
zone is very closely related to improvement in fasting and
postprandial EGP in type 2 diabetes. Diabetes 57:2288–2295,
2008
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epatic triglyceride has been shown to be
strongly associated with hepatic insulin resis-
tance in type 2 diabetes (1–3). The exact mech-
anism by which hepatic triglyceride induces
hepatic insulin resistance is unknown but is thought to
relate to accumulation of intracellular fatty acid metabo-
lites and consequent activation of a serine kinase cascade
and induction of cellular insulin resistance (4). Reduction
in hepatic triglyceride content by moderate weight reduc-
tion normalizes rates of basal endogenous glucose produc-
tion (EGP) in patients with type 2 diabetes (2). Hepatic
insulin resistance is also associated with impaired post-
prandial suppression of EGP in type 2 diabetes, but the
effect of reduction of hepatic triglyceride content on
postprandial suppression of EGP in type 2 diabetes is
unknown.
Thiazolidinediones, such as pioglitazone, possess insu-
lin-sensitizing properties and have been shown to decrease
hepatic triglyceride content in type 2 diabetes (5). Because
thiazolidinediones have been shown to reduce both fasting
and postprandial glucose levels (6,7), we hypothesized
that pioglitazone treatment in type 2 diabetes would
reduce hepatic triglyceride content and consequently re-
duce basal and postprandial EGP. In addition, visceral fat
has also been implicated in hepatic insulin resistance, and
pioglitazone has been reported to decrease visceral fat
content (8). The effect of this on EGP requires deﬁnition.
To test our hypothesis, we used noninvasive
1Hm a g -
netic resonance spectroscopy to assess hepatic triglycer-
ide and intramyocellular triglyceride content and magnetic
resonance imaging to quantify intra-abdominal fat content
in 10 type 2 diabetic patients before and after treatment
with pioglitazone. EGP was measured using a dynamic
isotopic methodology after a standard liquid test meal.
RESEARCH DESIGN AND METHODS
We studied 10 suboptimally controlled healthy subjects with type 2 diabetes (6
men and 4 women; 9 Caucasians and 1 Asian; 2 years duration; mean age
52.1  2.8 years; age range 38–64 years; A1C 7.5%; and no history of weight
loss or ketonuria at diagnosis) on maximum-tolerated sulfonylurea treatment,
who required additional antidiabetes medications. Apart from sulfonylurea
treatment, no subject was taking any medications that would affect glucose or
lipid metabolism, and subjects on statins were excluded. Subjects who had
previous treatment with metformin, thiazolidinediones, or insulin and those
with history of noncompliance with treatment were excluded. Two subjects
were on tolbutamide, three were on glimiperide, and ﬁve were on gliclazide
treatment.
After a 4-week run-in period to ensure metabolic stability, 30 mg pioglita-
zone once daily was given for 16 weeks. Two metabolic study days were
undertaken: one before and one after pioglitazone treatment. Localized
1H
magnetic resonance spectra of liver and skeletal muscle and abdominal fat
distribution were obtained before and after completion of pioglitazone
treatment. The study protocol was approved by the Newcastle and North
Tyneside Local Research Ethics Committee. Full verbal and written explana-
tion was given, and written consent was obtained before commencement of
the studies.
Each subject was studied twice: once before pioglitazone treatment and
once after 16 weeks of pioglitazone treatment. Subjects refrained from alcohol
or vigorous exercise for 3 days before the study day and consumed their
habitual weight-maintaining diet. After a 12-h overnight fast, all subjects
arrived at 0700 h, and anthropometric measurements were recorded. Bio-
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and the percentage of body fat was derived. An intravenous cannula for
infusion was sited in an antecubital fossa vein and a second cannula in a distal
forearm vein, this hand being placed in a heated box at 50°C to allow sampling
of arterialized blood. Baseline blood samples were then taken. After patients
were rested for 30 min, at time 120 min, a fasting plasma glucose–adjusted
prime of 6,6-dideuterated glucose was given intravenously (9), and a contin-
uous infusion of 6,6-dideuterated glucose (0.04 mg  ml
1  min
1) was
commenced. A period of 120 min was allowed for equilibrium of 6,6-
dideuterated-glucose; the end of this period was taken to be time 0. At this
time, a standard liquid test meal (100 g carbohydrate, 12.5 g fat, and 16 g
protein) containing 2 g 2-deuterated glucose was given, and the subjects
consumed this over a 10-min period. The rate of infusion of 6,6-dideuterated
glucose was adjusted in a stepwise fashion to match the anticipated pattern of
endogenous glucose release after the meal and was as follows: 120 to 0 min,
100% of basal infusion rate; 0–3 min, 100%; 3–8 min, 70%; 8–18 min, 55%; 18–28
min, 30%; 28–45 min, 15%; 45–70 min, 25%; 70–160 min, 35%; 160–270 min,
55%; and 270–360 min, 80%. The metabolic study was ﬁnished at 360 min. The
rate of infusion was determined iteratively from eight pilot studies. Plasma
enrichments of 6,6-dideuterated glucose were analyzed in each pilot study,
and rate of infusion was modiﬁed in subsequent studies until the anticipated
pattern of EGP was mimicked.
Frequent blood samples were taken for measuring plasma glucose, 2-deu-
terated glucose, 6,6-dideuterated glucose, triglycerides, free fatty acids
(FFAs), insulin, C-peptide, and glucagon. Substrate oxidation rates were
calculated from indirect calorimetry data derived from constant ﬂow hood
calorimeter (Delta Trac 17), using standard formulas (10). In one subject, the
after-pioglitazone study was terminated at 260 min because of symptoms of
hypoglycemia (blood glucose 3.7 mmol/l). The same subject had reported
symptoms of hypoglycemia during the pioglitazone treatment period, and the
sulfonylurea dose had been reduced. The study was stopped at 120 min after
meal ingestion in one other subject on both study days because of vasovagal
symptoms.
Metabolite and hormone assays. Plasma glucose was measured on a Yellow
Springs glucose analyzer (Yellow Springs Instruments, Yellow Springs, OH).
FFA was measured on a Roche Cobas centrifugal analyzer using a Wako kit
(Wako Chemicals, Neuss, Germany). Plasma triglycerides were measured on
a Roche Cobas centrifugal analyzer using a colorimetric assay (ABX Diagnos-
tics, Montpellier, France). Serum insulin and C-peptide assays were both
measured using Dako ELISA kits (Dako, Ely, Cambridge, U.K.). Plasma
glucagon was measured using the glucagon radioimmunoassay kit (Linco
Research, St. Charles, MO), and tubes were counted using a Packard Cobra
gamma counter.
2H2 percent enrichment in plasma glucose was determined by
gas chromatography–mass spectroscopy using a Thermo Voyager single
quadrupole mass spectrometer interfaced to a Thermo Trace GC, with
automated injection via a Thermo AS2000 autosampler (Thermo Scientiﬁc,
Waltham, MA). The coefﬁcient of variation (CV) for the precision of plasma
2H2 atom percent excess (APE) measurement was 4.1%.
Calculations of EGP. The proﬁle of exogenous glucose concentration, i.e.,
the component of total glucose concentration due to exogenous glucose
ingestion, was initially calculated from 2-deuterated glucose (11). We then
calculated the time course of the endogenous glucose concentration, i.e., the
component of total glucose due to EGP only, by subtracting the calculated
exogenous component and the 6,6-dideuterated glucose concentration from
the measured total glucose concentration. The steady-state values of plasma
clearance rate and basal EGP (basal EGP  plasma clearance rate  basal
glucose concentration) were estimated from the 6,6-dideuterated glucose
decay curve after the prime dose of 6,6-dideuterated glucose given 2 h before
the meal (12). Because 6,6-
2H2-glucose had been infused mimicking the
expected behavior of EGP, the ratio of 6,6-
2H2-glucose to endogenously
produced glucose was almost constant (tracer-to-tracee clamp technique),
allowing reliable estimation of EGP (13). EGP was calculated using both the
model of Steele et al. (14,15) and the two-compartment model of Radziuk et al.
(16), with the tracer-to-tracee ratio derivative calculated after the signal was
smoothed using an algorithm based on stochastic nonparametric deconvolu-
tion (17). Calculated EGP was similar in both models, and the results from the
Steele model are presented. In three subjects, the EGP proﬁles could not be
assessed because of modeling factors in the postprandial period, and their
data were excluded from the EGP analysis. Relationships between EGP and
its determinants were determined in all subjects with paired data available
(seven subjects).
1H magnetic resonance spectroscopy. Localized
1H nuclear magnetic
resonance spectra of liver and muscle were obtained in a 1.5-Tesla magnetic
resonance scanner with a
1H transmitter/receiver coil placed over the relevant
tissue. Liver spectra were acquired by applying the breath hold–triggered
stimulation echo acquisition sequence. Spectra were collected without water
suppression, using a point-resolved spectroscopy sequence (18), with a 2- 
2-  2-cm voxel in the soleus muscle and anterior tibialis muscle and a 3- 
3-  3-cm voxel in the liver, using an echo time of 25 ms and repetition time
of 5,000 ms with 32 acquisitions and a spectral resolution of 1 Hz.
Spectra were analyzed using an magnetic resonance user interface (19).
Automatic phase correction was performed using the water peak in the
spectra, and the water peak was assigned to 4.68 ppm. Lipid spectral peaks
were assigned as described in Boesch et al. (20), and spectra peak amplitudes
were estimated by ﬁtting Lorentzian curves to the spectra. To calculate molar
density of triglycerides from the amplitudes of water and intramyocellular
lipid estimated in the spectral ﬁtting, we used the formulas described by
Szczepaniak et al. (21).
Abdominal fat distribution. The volume of total and visceral fat compart-
ments was determined as described previously (22). To determine the visceral
fat content, a region encompassing the viscera was drawn manually by an
operator using a computer mouse. The visceral fat volume was determined by
multiplying the number of pixels brighter than the threshold in this region by
the pixel size and slice thickness. Regions were also drawn manually around
brightly appearing structures such as bone marrow to subtract their contri-
bution from the total fat volume. The subcutaneous fat volume was quantiﬁed
by subtracting the visceral fat volume from the total fat volume. The
intrasubject CVs in measurement of subcutaneous and visceral fat were 4.9
and 3.8%, respectively.
Statistical analysis. All data are expressed as means  SE. Statistical
analyses were performed using MINITAB software (Minitab, State College,
PA). Comparisons were carried out using Student’s two-tailed t test where
appropriate, and Wilcoxon’s signed-rank test was used to compare EGP.
Relationships were tested using the linear correlation analysis. Stepwise
regression analysis was used for determining the determinants of EGP. A P
value of 0.05 was considered to indicate statistical signiﬁcance.
RESULTS
Plasma glucose, A1C, and body weight. Fasting mean
plasma glucose (10.1  0.5 vs. 7.8  0.5 mmol/l, P  0.02)
and A1C (8.6  0.3 vs. 6.7  0.38% P  0.001) were
signiﬁcantly lower after pioglitazone treatment (Table 1).
After 16 weeks of pioglitazone treatment, both body
weight and BMI increased signiﬁcantly, and increases in
both fat mass and fat-free mass contributed to the overall
weight gain (Table 1).
After meal ingestion, plasma glucose rose on both study
days, but mean peak plasma glucose was signiﬁcantly
lower (18.7  2.3 vs. 15.6  3.8 mmol/l, P  0.05) and
delayed (100 vs. 150 min) after pioglitazone treatment. The
postprandial plasma glucose remained signiﬁcantly lower
until the end of the study (360 min, 9.4  1.0 vs. 6.5  0.8
mmol/l, P  0.04) (Fig. 1A).
Plasma insulin and C-peptide. Fasting insulin levels
(102.2  14.8 vs. 81.1  14.8 pmol/l, NS) and after-meal
mean peak insulin levels (506.2  62.5 vs. 464.5  87.5
pmol/l, NS) did not change signiﬁcantly after pioglitazone
treatment (Fig. 1B). However, fasting C-peptide levels
were signiﬁcantly reduced after pioglitazone treatment
(1.3  0.1 vs. 1.0  0.1 nmol/l, P  0.005) and remained
signiﬁcantly lower until measured 80 min postprandially
(Fig. 1C).
Insulin secretion rates and hepatic insulin extrac-
tion. Using C-peptide and plasma insulin levels, insulin
secretion rate and hepatic insulin extraction were derived.
Insulin secretion rates were similar in the postprandial
period both at baseline and after pioglitazone treatment
(peak insulin secretion rate 1,197  125 vs. 1,205  165
pmol/min; NS). Similarly, mean postprandial hepatic insu-
lin extraction was unchanged after pioglitazone treatment
(39.3  0.01 vs. 40.2  0.01%, NS).
Glucagon. Fasting glucagon levels were signiﬁcantly de-
creased on pioglitazone treatment (150.9  24.2 vs.
112.4  17.2 pg/ml, P  0.005), and there was a lower and
delayed postprandial peak (207.4  24.1 pg/ml at 20 min
vs. 150.1  23.9 pg/ml at 40 min, P  0.01). Postprandial
B. RAVIKUMAR AND ASSOCIATES
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days and then rose slightly on both study days during the
postabsorptive period (Fig. 1D).
FFA and triglyceride. Fasting plasma FFA levels were
slightly but not statistically signiﬁcantly lower (0.73  0.08
vs. 0.66  0.05 mol/l, NS). Postprandially, FFA concen-
trations were suppressed on both study days, more so
after pioglitazone treatment (0.20  0.04 vs. 0.08  0.02
mol/l at 150 min [nadir], P  0.018). Levels remained
signiﬁcantly lower until 210 min (0.22  0.04 vs. 0.10 
TABLE 1
Anthropometric and laboratory measurements before and after pioglitazone treatment for 16 weeks
Before pioglitazone After pioglitazone P value
Body weight (kg) 87.4  4.7 93.6  4.7 0.001
BMI (kg/m
2) 31.2  1.2 33.0  1.1 0.001
Fat mass (kg) 32.9  3.5 35.6  3.4 0.001
Fat-free mass (kg) 54.6  3.5 58.0  3.5 0.001
A1C 8.6  0.3 6.7  0.3 0.001
Fasting plasma glucose (mmol/l) 10.1  0.5 7.8  0.5 0.02
Peak plasma glucose (mmol/l) 18.7  2.3 15.6  3.8 0.05
Fasting plasma insulin (pmol/l) 102.2  14.8 81.1  14.8 NS
Fasting plasma C-peptide (nmol/l) 1.3  0.1 1.0  0.1 0.005
Fasting plasma triglyceride (mmol/l) 2.3  0.4 1.9  0.6 NS
Fasting plasma FFA (mol/l) 0.73  0.08 0.66  0.05 NS
Baseline glucagon (pg/ml) 150.9  24.2 112.4  17.2 0.005
Date are means  SE.
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FIG. 1. Change in plasma glucose (A), plasma insulin (B), plasma C-peptide (C), and plasma glucagon (D) before and after the meal and before
(E) and after (F) pioglitazone treatment. Data are means  SE.
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2290 DIABETES, VOL. 57, SEPTEMBER 20080.02 mol/l, P  0.03) (Fig. 2A). Fasting plasma triglycer-
ide levels were slightly lower after pioglitazone treatment
(2.3  0.4 vs. 1.9  0.6 mmol/l, NS) and remained lower
throughout the postprandial period (Fig. 2B).
EGP. At the end of the ﬁrst 120-min basal period, mean
plasma APEs of 6,6-
2H2-glucose were 1.48  0.05 and
1.61  0.09 before and after pioglitazone treatment, re-
spectively. The consequent rate of fall of plasma 6,6-
2H2-
glucose APE on the change in infusion protocol was
similar during the postprandial period on both study days
(31 and 38% at 30 min and 47 and 51% at 60 min). At nadir,
between 120 and 180 min, plasma APEs were 0.6  0.01
and 0.7  0.01 before and after pioglitazone treatment,
respectively. Fasting EGP was signiﬁcantly reduced after
pioglitazone treatment (16.6  1.0 vs. 12.2  0.7 mol 
kg
1  min
1, P  0.005) (Fig. 3). Although postprandial
suppression of EGP was rapid on both study days (at 40
min, 96% suppression [baseline study] and 93% suppres-
sion [pioglitazone study]), postprandial EGP was signiﬁ-
cantly lower at 150 min after pioglitazone treatment
(2.50  0.61 vs. 0.82  0.25 mol  kg
1  min
1, P  0.05).
Between 80 and 260 min, mean EGP was twofold lower
after pioglitazone treatment (2.58  0.25 vs. 1.26  0.30
mol  kg
1  min
1, P  0.001) (Fig. 3). When expressed
as percentage suppression from baseline, postprandial
suppression was still greater after pioglitazone treatment
(82 vs. 90%, between 180 and 210 min, P  0.02). Fasting
EGP was directly correlated with hepatic triglyceride
content before and after pioglitazone treatment (r  0.64,
P  0.01) (Fig. 4A). Likewise, hepatic triglyceride content
correlated inversely with percentage suppression of EGP
at 150 min (r  0.63, P  0.02) (Fig. 4B). There was a
strong negative correlation between FFA levels at nadir
(150 min) and percentage suppression of EGP at 210 min
(r  0.87, P  0.001) (Fig. 4C). A stepwise regression
analysis, with EGP (fasting and postprandial) as the de-
pendent variable and hepatic triglyceride, muscle triglyc-
eride, plasma insulin, plasma glucagon, visceral fat,
plasma FFA, age, and BMI as independent variables
showed that for fasting EGP, hepatic triglyceride was the
most signiﬁcant and independent variable (step 1, adjusted
r
2  53, P  0.001) followed by fasting plasma glucagon
(step 2, adjusted r
2  84; P  0.005). For postprandial
percentage suppression of EGP at 150 min, hepatic triglyc-
eride was the only signiﬁcant and independent variable
(step 1, adjusted r
2  36; P  0.03). There was no
independent relationship between changes in plasma glu-
cagon or molar insulin-to-glucagon ratio with EGP.
1H magnetic resonance spectroscopy. Despite increase
in body weight, hepatic triglyceride content decreased by
50% after pioglitazone treatment (140.1  28.1 vs. 67.0 
10.3 mol/g, P  0.03) (Fig. 5A), and tibialis anterior
muscle triglyceride content decreased by 55% (8.37  1.6
vs. 3.65  1.14 mol/g, P  0.02) (Fig. 5B). Soleus
triglyceride content was slightly lower after pioglitazone
treatment (23.8  3.3 vs. 20.8  3.1 mol/g, NS). Intramyo-
cellular triglyceride content did not correlate with fasting
(r  0.27, P  0.37) or mean postprandial EGP (80–260
min; r  0.19, P  0.52).
Abdominal fat content. Pioglitazone treatment was as-
sociated with a signiﬁcant increase in subcutaneous fat
content (10.8  1.4 vs. 12.5  1.7 l, P  0.003) (Fig. 5D)
and decreased visceral fat–to–subcutaneous fat ratio
(0.68  0.1 vs. 0.57  0.1, P  0.02). Total visceral fat
content was unchanged (6.2  0.3 vs. 6.2  0.5 l, NS) (Fig.
5C). Visceral fat content did not correlate with fasting (r 
0.05, P  0.88) or mean postprandial EGP (80–260 min)
(r  0.01, P  0.76).
Substrate oxidation. Fasting glucose oxidation was sig-
niﬁcantly lower (2.2  0.2 vs. 1.5  0.2 mg  kg
1  min
1,
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18 and 12% of fasting glucose disposal before and after
pioglitzone treatment, respectively. Postprandial glucose
oxidation remained lower after pioglitazone treatment
until 120 min after the meal. Fasting (0.4  0.1 vs. 0.2  0.1
mg  kg
1  min
1, NS) and postprandial lipid oxidation
(0.2  0.1 vs. 0.1  0.1 mg  kg
1  min
1, NS) were slightly
but not signiﬁcantly lower after pioglitazone treatment.
Resting and postprandial energy expenditure was similar
on both study days.
DISCUSSION
In keeping with our hypothesis, pioglitazone treatment in
type 2 diabetes resulted in an 50% decrease in hepatic
triglyceride and 55% reduction in muscle triglyceride,
despite signiﬁcant weight gain (6 kg). This was associ-
ated with a 26% decrease in fasting EGP and a twofold
decrease in postprandial EGP. Hepatic triglyceride con-
tent was directly correlated with fasting EGP (r  0.64,
P  0.01) and inversely correlated with percentage sup-
pression of EGP (time 150 min, r  0.63, P  0.02)
before and after pioglitazone treatment. By stepwise re-
gression, hepatic triglyceride was found to be a signiﬁcant
independent predictor of fasting EGP, accounting for 53%
of its variation (P  0.001). Similarly, hepatic triglyceride
content accounted for 36% of the variation seen in the
percentage suppression of postprandial EGP observed at
150 min (P  0.03). In contrast, although muscle triglyc-
eride content decreased with pioglitazone treatment, it did
not correlate with EGP. There was no relationship be-
tween visceral fat content with EGP.
In type 2 diabetes, hepatic insulin resistance is believed
to underlie the elevated basal rates of EGP and subnormal
postprandial suppression of EGP (23,24). In a recent
study, elevated EGP was found to be a primary mechanism
for postprandial hyperglycemia in type 2 diabetes (25).
Hepatic triglyceride content is characteristically increased
in type 2 diabetes and is an important predictor of hepatic
insulin resistance (1,26), and this is true even independent
of obesity (27). In addition, hepatic triglyceride content
correlated negatively with postprandial net hepatic glyco-
gen synthesis in type 2 diabetes (3). Although the exact
cause of the excess accumulation of hepatic triglyceride in
type 2 diabetes is unclear, we have previously shown this
is likely to be at least partly secondary to increased
postprandial uptake of dietary fatty acids by the liver (28).
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FIG. 4. Correlation between fasting EGP and liver fat content (r 
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ery from visceral depots and reduced intrahepatic FFA
oxidation (29).
Hepatic steatosis induced by 3-day high-fat feeding
resulted in reduced insulin activation of insulin receptor
substrate (IRS)-1– and IRS-2–associated phosphatidylino-
sitol 3-kinase activity, increased gluconeogenesis, and
liver-speciﬁc insulin resistance (30). By reversal of this
principle, a very–low-fat diet induced decrease in hepatic
triglyceride in patients with type 2 diabetes was shown to
markedly improve both EGP suppression during insulin
infusion and hepatic insulin sensitivity (2). Similarly, we
observed a 50% decrease in hepatic triglyceride content
after pioglitazone treatment (Fig. 5A), and this was asso-
ciated with signiﬁcant improvement in fasting and post-
prandial EGP (Fig. 3).
Increased EGP in type 2 diabetes is contributed to by
both increased gluconeogenesis and glycogenolysis (25),
but the effect of gluconeogenesis may predominate
(31,32). The results of this study suggest that pioglitazone-
induced reduction in EGP is likely to reﬂect changes in
either gluconeogenesis and/or glycogenolysis. In a recent
study, pioglitazone treatment improved fasting and post-
prandial glycemia, principally via inhibition of gluconeo-
genesis (33). The effect of thiazolidinediones on
glycogenolysis is yet to be determined. Pioglitazone has
been shown to decrease gluconeogenesis (34) and to
inhibit expression of key genes involved in gluconeogen-
esis (35). In addition, FFAs are potent stimulators of
gluconeogenesis, and thiazolidinediones decrease FFA
levels (36,37). Pioglitazone also markedly increases adi-
ponectin levels (38,39), and adiponectin has been shown
to decrease gluconeogenesis and EGP (40,41). Hyperglu-
cagonemia is associated with increased basal EGP (42),
and we observed a major decrease in fasting glucagon
levels after pioglitazone treatment. Because fasting insulin
levels were relatively unchanged after pioglitazone treat-
ment, the effect of pioglitazone on fasting EGP is likely to
be secondary to its effect, either directly or indirectly, on
the liver.
We observed that the initial postprandial suppression of
EGP both before and after pioglitazone was relatively
normal. Using a similar dynamic tracer methodology, we
have previously reported similar initial postprandial sup-
pression of EGP in subjects with type 2 diabetes compared
with matched controls (43). The conventional dual tracer
approach with ﬁxed priming and ﬁxed-rate tracer infusion
has been extensively used to measure EGP and documents
subnormal suppression of EGP in type 2 diabetes (44,45).
However, by infusing the intravenous tracer to mimic the
expected pattern of EGP, the tracer-to-tracee ratio is
maintained at an approximate constant, and the EGP
estimate is model independent and is not overestimated
(43). This has recently been quantitatively assessed (13).
In contrast to our observations, a recent study reported a
much slower rate of suppression of EGP after pioglitazone
(33), and this is likely to be a consequence of using a
ﬁxed-rate tracer infusion for a dynamic meal study.
The rapid early suppression of EGP needs to be consid-
ered. Hepatic insulin action is relatively unimpaired at
high insulin levels (46), and glucose effectiveness is also
preserved in type 2 diabetes (47). In the immediate post-
prandial period, the change in plasma FFAs is fairly subtle,
and glucagon levels actually rise. It has been suggested
that FFA concentrations signal the suppression of EGP
(portal hypothesis) (48). However, our data do not support
this because there is robust suppression (75%) of EGP
despite only an 15% decrease in FFAs by the 30-min
postprandial measurement. It is hence most likely that the
direct effect of rising hepatic sinusoidal insulin is the
primary determinant of EGP in this period.
Impaired postprandial suppression of FFAs and gluca-
gon is a characteristic feature of type 2 diabetes (44,49),
and both FFAs and glucagon (25,50,51) have been impli-
cated in the abnormal regulation of EGP. Recently, Woerle
et al. (25) have demonstrated that postprandial EGP was
signiﬁcantly correlated with insulin-to-glucagon molar ra-
tio, with postprandial decrements in both plasma glucagon
and plasma FFAs. In the current study, between 80 and 260
min after the meal, pioglitazone treatment resulted in a
twofold greater suppression of EGP compared with pre-
treatment. Unlike the immediate postprandial period, in-
sulin levels fall during this period, and FFAs and glucagon
may exert a more pronounced effect on EGP. Insulin levels
and insulin secretion rates were relatively unchanged
between the 2 study days, but postprandial FFA and
glucagon levels were signiﬁcantly lower after pioglitazone
treatment. We observed a strong correlation between the
nadir FFA levels and percentage suppression of EGP at
210 min (Fig. 4C). Hence, it is likely that pioglitazone-
induced interruption of intrahepatic fatty acid supply may
underlie the beneﬁcial effects of EGP during this time.
Although pioglitazone treatment decreased muscle tri-
glyceride content as seen in previous studies (52,53), we
observed no correlation between muscle triglyceride and
EGP. The mechanism of reduction of muscle triglyceride
by pioglitazone is unclear. Pioglitazone is postulated to
increase tissue fatty acid oxidation through its effect on
increasing adiponectin and consequent activation of aden-
osine monophosphate–activated protein kinase (53), but
muscle fatty acid oxidative enzyme levels were not ob-
served to change after pioglitazone treatment in a recent
study (52). In contrast to previous studies, we did not
observe any signiﬁcant change in visceral fat content after
pioglitazone treatment. The fact that EGP improved inde-
pendent of change in visceral fat content implies that
visceral fat is unlikely to be a critical determinant of EGP,
and this clearly refutes the portal hypothesis in the control
of EGP (48).
Potential shortcomings of the study must be considered.
First, the small study sample size is a potential weakness
of the study, but the subject characteristics are typical for
type 2 diabetes, and the main ﬁndings are clear-cut. The
small sample size is also likely to explain the lack of
statistical signiﬁcance of lipid oxidation between the study
days. Second, the study was a within-subject comparative
study by design and did not have a placebo arm. Third,
gluconeogenesis and glycogenolysis were not separately
quantiﬁed; hence, the precise mechanism of reduction in
EGP with pioglitazone could not been determined. None-
theless, the study deﬁnes the precise effects of pioglita-
zone on postprandial glucose metabolism and the
determinants of EGP in type 2 diabetes.
In summary, we have demonstrated that 16-week treat-
ment with pioglitazone improves fasting and postprandial
EGP suppression and decreases liver and muscle triglyc-
eride content despite overall increase in body weight.
Increased hepatic triglyceride content is associated with
subnormal postprandial suppression of EGP and is an
independent determinant of fasting and postprandial EGP.
This study provides further insight into the mechanism of
action of pioglitazone and suggests that hepatic triglycer-
B. RAVIKUMAR AND ASSOCIATES
DIABETES, VOL. 57, SEPTEMBER 2008 2293ide is a useful therapeutic target for management of type 2
diabetes.
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